Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human FS222 study in advanced malignancies
NL-OMON60601Phase 1Active, not recruiting
- Sponsor
- invoX Pharma
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FS222 in Non-hematologic malignancy and hematopoietic malignancies, sponsored by invoX Pharma. Primary endpoint: Primary endpoint(s). Started May 2025; status: active, not recruiting.
02
Drugs
FS222
03
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON60601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60601.